RA Capital Management’s Vor Biopharma VOR Stock Holding History

RA Capital Management’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$96.4M	Hold	5,404,998	–	–	1.02%	22
2025 Q4	$70.7M	Buy	5,404,998 +3,422,697	+173%	+$63.7M	0.72%	26
2025 Q3	$96.6M	Sell	1,982,301 -1	-0%	-$40	1.19%	23
2025 Q2	$64.2M	Hold	1,982,302	–	–	1.08%	24
2025 Q1	$28.4M	Hold	1,982,302	–	–	0.48%	33
2024 Q4	$44M	Buy	1,982,302 +844,858	+74%	+$14M	0.59%	36
2024 Q3	$15.9M	Hold	1,137,444	–	–	0.18%	58
2024 Q2	$22.7M	Hold	1,137,444	–	–	0.3%	50
2024 Q1	$53.9M	Hold	1,137,444	–	–	0.69%	40
2023 Q4	$51.2M	Hold	1,137,444	–	–	0.8%	32
2023 Q3	$48.2M	Hold	1,137,444	–	–	0.95%	31
2023 Q2	$70.3M	Hold	1,137,444	–	–	1.33%	23
2023 Q1	$122M	Hold	1,137,444	–	–	2.77%	9
2022 Q4	$151M	Buy	1,137,444 +581,395	+105%	+$57.5M	3.07%	8
2022 Q3	$44.3M	Hold	556,049	–	–	0.94%	36
2022 Q2	$55.3M	Hold	556,049	–	–	1.47%	21
2022 Q1	$67.2M	Hold	556,049	–	–	1.47%	19
2021 Q4	$129M	Hold	556,049	–	–	2.28%	11
2021 Q3	$174M	Hold	556,049	–	–	2.42%	9
2021 Q2	$207M	Hold	556,049	–	–	3.33%	5
2021 Q1	$479M	Buy	+556,049	New	+$470M	7.23%	3

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RA Capital Management's VOR Position: Q1 2026 in Review

RA Capital Management held its Vor Biopharma (VOR) position steady in Q1 2026 at 5,404,998 shares worth $96.4M. The position accounts for 1.02% of the portfolio, ranked #22.

RA Capital Management first reported a position in VOR in Q1 2021 and has held it in 21 quarters since. The position peaked at $479M in Q1 2021. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

RA Capital Management held 5,404,998 shares of Vor Biopharma worth $96.4M as of Q1 2026.
RA Capital Management left its Vor Biopharma share count unchanged in Q1 2026.
Vor Biopharma made up 1.02% of RA Capital Management's portfolio in Q1 2026, its #22 holding.
RA Capital Management first reported a position in Vor Biopharma in Q1 2021 and has held it in 21 quarters since.
RA Capital Management's Vor Biopharma position peaked at $479M in Q1 2021.
80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.